Pfizer (PFE) Short term Debt (2009 - 2026)

Pfizer (PFE) has 18 years of Short term Debt data on file, last reported at $3.9 billion in Q1 2026.

• Short term Debt for Q1 2026 came in at $3.9 billion, down 12.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 12.98% YoY), and the FY2025 annual result was $3.2 billion, down 54.59% from the prior year.
• Short term Debt grew to $3.9 billion in Q1 2026 per PFE's latest filing, from $3.2 billion in the prior quarter.
• Over five years, Short term Debt peaked at $11.9 billion in Q2 2024 and troughed at $645.0 million in Q2 2022.
• A 5-year average of $5.4 billion and a median of $4.3 billion in 2025 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2022 and 2023: Short term Debt sank 85.18% in 2022, then jumped 549.3% in 2023.
• A 5-year view of Short term Debt shows it stood at $2.9 billion in 2022, then soared by 251.44% to $10.4 billion in 2023, then plunged by 32.89% to $6.9 billion in 2024, then plunged by 54.59% to $3.2 billion in 2025, then rose by 23.34% to $3.9 billion in 2026.
• Business Quant data shows PFE's Short term Debt at $3.9 billion in Q1 2026, $3.2 billion in Q4 2025, and $4.3 billion in Q3 2025.